DRD1 and type 2 diabetes mellitus: Bioinformatic analysis, qRT-PCR validation, and promoter activity detection revealed that miR-195-5p exhibited clinical significance in the aforementioned 50 EH patients with T2DM by directly targeting the 3′-UTR of dopamine receptor D1 (DRD1) and inducing its subsequent downregulation.